Apellis Pharmaceuticals Inc — Quarterly Financial Statistics (NASDAQ:APLS) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -34.1 M-19.36 M53.41 M-4.45 M10.54 M-14.18 M 45.33 M Cash from investing activities 020 K8 00049 K148 K108 K 313 K Cash from financing activities 2.54 M-4 M274 K6.56 M793 K1.26 M 8.88 M Free cash flow -34.1 M-19.38 M53.4 M-4.49 M10.39 M-14.28 M 45.01 M

Nouvelles

Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y

H.C. Wainwright relève l’objectif de cours d’Apellis sur les perspectives de Syfovre

H.C. Wainwright raises Apellis stock price target on Syfovre outlook

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript

Le BPA de Apellis Pharma a dépassé les attentes de 0,85$, le CA a surpassé les prévisions

Apellis Pharma earnings beat by $0.85, revenue topped estimates

Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates

Résultats T4 2025 d’Apellis : croissance des deux produits

Apellis Q4 2025 slides: dual product growth, path to profitability

Apellis Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:APLS) 2026-02-24

Résultats d’Apellis : le nouveau médicament rénal peut-il relancer la croissance ?

Apellis earnings on deck: Can new kidney drug revive growth momentum?